Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5184870 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Background: Alzheimer's disease (AD) is a devastating condition with no known effective treatment. We have demonstrated cerebral endothelin B receptors (ETBR) as a potential target to treat AD. However, the mechanism of action of sovateltide remains elusive.
View Article and Find Full Text PDFBackground: Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by the accumulation of neurofibrillary tangles (NFTs) which consist primarily of hyperphosphorylated tau protein. Abnormal phosphorylated tau has been considered as a pathogenic species that impairs cellular function and propagates from neuron to neuron. AD affects millions of people around the world, however, there's no effective drug that can prevent or cure the disease to date.
View Article and Find Full Text PDFInhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung.
Nat Commun
January 2025
Center for Infection and Immunity, Guangdong Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.
Suppression of chimeric antigen receptor-modified T (CAR-T) cells by the immunosuppressive tumor microenvironment remains a major barrier to their efficacy against solid tumors. To address this, we develop an anti-PD-L1-expressing nanovesicle loaded with the STING agonist cGAMP (aPD-L1 NVs@cGAMP) to remodel the tumor microenvironment and thereby enhance CAR-T cell activity. Following pulmonary delivery, the nanovesicles rapidly accumulate in the lung and selectively deliver STING agonists to PD-L1-overexpressing cells via the PD-1/PD-L1 interaction.
View Article and Find Full Text PDF"Current and emerging drug therapies in Alzheimer's disease: A pathophysiological Perspective".
Neuroscience
January 2025
Department of Biosciences, Institute of Management Studies Ghaziabad 9(University Courses Campus), NH09, Adhyatmik Nagar, Ghaziabad, Uttar Pradesh, India. Electronic address:
The analytical and experimental investigation of several targets and biomarkers that help in explaining significant cognitive deficits, covering drug development and precision medicine aimed at different chronic neurodegenerative conditions such as Alzheimer's disease (AD), Parkinson's disease, synaptic dysfunction, brain damage from neuronal apoptosis, and other disease pathologies; this served as the foundation for all phase studies. The focus of current therapeutic approaches is on developing humanized antibodies, agonist and antagonist drugs, receptors, signaling molecules, major targeted drug-metabolizing enzymes, and other metabolites to treat neurodegeneration in the AD brain brought on by tau hyperphosphorylation, amyloid plagues, or other cholinergic effects. The five A's-amnesia, agnosia, aphasia, apraxia, and anomia-are the typical symptoms associated with AD.
View Article and Find Full Text PDFUnraveling Glioblastoma: TME Implication and Gene Therapy Advances.
Curr Gene Ther
November 2024
Department of Biomedical Sciences, School of Biosciences & Technology, VIT, Vellore Dt. PIN:632014, India.
Glioblastoma is a malignant manifestation of a solid brain tumour with a very dismal prognosis due to an overall median survival of 14 months. The currently administered Standard treatment plan, the STUPP regimen, is not very effective in tackling this neoplasia. A major concern that affects the development of new drug formulations, specifically for Glioma, is the inherent sub-clonal heterogeneity, which includes the dynamic and intricate nature of the Tumour Microenvironment (TME).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!